...

首页> 外文期刊>Current opinion in lipidology >Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?

【24h】

Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?

机译：ProProtein转化酶枯草杆菌蛋白酶/ kexin型9型抑制剂和脂蛋白（a）介导的动脉粥样硬化心血管疾病的风险：超过眼睛？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose of review

机译：审查的目的

著录项

来源
《Current opinion in lipidology》 |2019年第6期|共10页
作者
Boffa Michael B.; Koschinsky Marlys L.;
展开▼
作者单位

Univ Western Ontario Dept Biochem Schulich Sch Med &

Dent London ON Canada;

Univ Western Ontario Schulich Sch Med &

Dent Dept Physiol &

Pharmacol London ON Canada;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类生物化学;
关键词
atherosclerotic cardiovascular disease; cardiovascular outcome trials; lipoprotein(a); proprotein convertase subtilisin/kexin type 9;

机译：动脉粥样硬化心血管疾病;心血管结果试验;脂蛋白（A）;Proprotein转化酶枯草杆菌蛋白酶/ kexin型9;

相似文献

外文文献
中文文献
专利

1. Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye? [J] . Boffa Michael B., Koschinsky Marlys L. Current opinion in lipidology . 2019,第6期

机译：ProProtein转化酶枯草杆菌蛋白酶/ kexin型9型抑制剂和脂蛋白（a）介导的动脉粥样硬化心血管疾病的风险：超过眼睛？
2. Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial) [J] . Wong Nathan D. The American Journal of Cardiology . 2017,第7期

机译：用Proprotein转化酶枯草杆菌蛋白酶-kexin患者治疗动脉粥样硬化性心血管疾病患者后的残留风险（从升高风险试验中的受试者中的PCSK9抑制的进一步心血管结果研究）
3. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients [J] . Zenti Maria G., Altomari Anna, Lupo Maria G., European journal of preventive cardiology . 2018,第17期

机译：从脂蛋白血液蛋白/ kexin型9型抑制剂：对心血管疾病患者的对低密度脂蛋白胆固醇和C反应蛋白水平的影响
4. Towards Investigating the Role of Proprotein Convertase Subtilisin/Kexin Family (PCSK/7/9) in Cancer by Using Bioinformatics Motif Detection Technique [C] . Umar Draz, Sana Yasin, Shafiq Hussain, International Bhurban Conference on Applied Sciences and Technologies . 2021

机译：通过使用生物信息学主题检测技术来研究Proprotein转化酶枯草杆菌素/ kexin家族（PCSK / 7/9）的作用
5. Evaluation of the Interaction Between Proprotein Convertase Subtilisin/Kexin Type 9 and Sterol Carrier Protein-2 [D] . Ahranjani, Reza. 2017

机译：评价前蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型与甾醇载体蛋白2的相互作用。
6. Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation [O] . Tanja Kosenko, Mia Golder, Geoffrey Leblond, 2013

机译：低密度脂蛋白与人血浆中的前蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型（PCSK9）结合并抑制PCSK9介导的低密度脂蛋白受体降解
7. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease [O] . Christopher P. Cannon, Robert J. Sanchez, Alexa C. Klimchak, 2019

机译：Satisin Inorcance对ezetimibe的需求的影响和/或先前转化酶枯草杆菌蛋白/ kexin型9型抑制剂，用于满足具有动脉粥样硬化性心血管疾病的人群中低密度脂蛋白胆固醇目标

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号